Pluristem (PLRS.OB) Begins Trade on Frankfurt Stock Exchange
With the need for bone marrow for transplants outpacing the donors available, finding a way to provide the tissue so desperately needed for cancer patients has become one of the next medical frontiers.Pluristem Life Systems Inc. (OTCBB: PLRS) has been working to use stem cells to produce products that can treat various disorders and cancers. From its research facilities in Israel, the company's first planned product uses hematopoietic stem cells from umbilical cord blood to help address the need for matched tissue for bone marrow transplants. The company's PLX-I will improve the engraftment process for those stem cells. Pluristem says…